

First Batch of Cellnovo Insulin Cartridges Produced by Flex

Delivery of first batch demonstrates completion of tooling and high volume manufacturing line programme

Full scale manufacturing anticipated in H2 2016

Paris, France, September 6, 2016 - Cellnovo Group ("Cellnovo" CLNV:EN Paris), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system today announces that delivery of the first batch of its Insulin cartridges produced by Flex (Flextronics), has been received. The delivery of this first batch of cartridges demonstrates that the automated manufacturing solution developed by Flex is complete.

The cartridge assembly includes high precision molded parts, now produced in a medical device clean-room facility at Flex, which marks the completion of a significant investment programme in new tooling for long term mass production.

Flex and Cellnovo are now focused on documentation and testing building up to full scale manufacturing, which remains on track and targeted for the second half of 2016.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: "This represents a major milestone as we reach the final stages of our journey towards achieving full mass production of our diabetes management system. Demand for our product, which offers patients unrivalled freedom and flexibility combined with high levels of accuracy and unique connectivity features, remains high and increased production will enable us to continue our expansion across Europe and in due course, into the United States."

•••

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected all-in-one diabetes management system that helps make life easier for patients. Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.

For further information please visit www.cellnovo.com

About the Cellnovo Diabetes Management System

Compact, tubeless, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real-time.



The First Connected All-in-one Diabetes Management System

Contact

Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Emmanuel Huynh
+ 33 1 44 71 00 16

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu

Consilium Strategic Communications

Media Relations in United Kingdom
Amber Fennell, Chris Gardner, Chris Welsh, Laura
Thornton
+44 20 3709 5700
cellnovo@consilium.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV

